You are here

What’s the Stem Cells Buzz this Week? - MSCs for Clinical Trials, MSC-Exosomes in Cancer Progression, Evolution of Glioblastoma Stem-Like Cells, and WJ-MSC Differentiation to Osteoblasts!

Comment

Discuss

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Interferon-γ Primed MSCs for Clinical Trials

A large number of studies have demonstrated the safety of mesenchymal stem cell (MSC)-based treatments, and now, the focus has moved onto engineering MSCs to enhance their therapeutic value. Now, a new study from the lab of Edwin M. Horwitz (Ohio State University, Columbus, Ohio, USA) now reports on the generation of Interferon-γ (IFNγ) primed MSCs for future application in clinical trials. Guess et al. hope that this strategy will reduce the need to infuse thawed cryopreserved cells, which may present with a reduced cell potency. See STEM CELLS Translational Medicine for all the details.

p53 deficient-MSC-Exosomes Promote Cancer Progression

A new study from the labs of Hui Qian and Wenrong Xu (Jiangsu University, PR China) has assessed the impact of p53 status in mesenchymal stem cells (MSCs) on exosome secretion and cancer progression. Mao et al. now report that p53-null bone marrow-derived MSC exosomes deliver elevated levels of UBR2 (ubiquitin protein ligase E3 component n-recognin 2) to target cells to promote gastric cancer development and metastasis via the modulation of the Wnt/β-catenin pathway. See STEM CELLS now for all the fine print.

Genetic Evolution of Glioblastoma Stem-Like Cells

New research from Carla Boccaccio (University of Torino Medical School, Italy) and Gaetano Finocchiaro (Fondazione IRCCS Istituto Neurologico, Milan, Italy) reports the existence of phylogenetically-related glioblastoma stem-like cells (GSCs) in matched primary and recurrent Glioblastoma multiform (GBM) tumors. Orzan et al. also suggest that recurrent GSCs likely pre-exist in the untreated primary tumor and are both mutagenized and positively selected by chemo-radiotherapy. Head over to STEM CELLS now for a deeper delve into this important study.

Epigenetic Regulation of RUNX2 Induction during WJ-MSC Differentiation to Osteoblasts

A recent STEM CELLS study from the lab of Verónica Palma (Universidad de Chile, Chile) sought to discover the mechanisms behind the differentiation of Umbilical cord Wharton's jelly mesenchymal stem cells (WJ-MSC) to immature osteoblasts. Bustos et al. now report that the inhibition of JARID1B histone demethylase activity promotes the expression of the osteoblast master-regulator RUNX2 to promote osteoblastic potential. For all the details on this great new study, make your way over to STEM CELLS now!

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!